
What happened
Xometry, Inc. (NASDAQ: XMTR) director Randolph Altschuler sold 15,721 shares on 2026-10-01 and 2026-10-02, the filing shows. The shares sold for $101.39 to $106.36 each, and the Form 4 puts the total value at about $1.63 million. After the sales, Altschuler held 423,029 shares.
The filing says the shares were sold in several transactions on both dates. It says the 10/01 sales were under a Rule 10b5-1 plan adopted by Altschuler's spouse at least 90 days earlier. It says the 10/02 sales were under a Rule 10b5-1 plan adopted by Altschuler at least 90 days earlier.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 15,721 shares | SEC Form 4 | |
| Sale price range | $101.39 to $106.36 per share | SEC Form 4 | |
| Reported total value | about $1.63 million | SEC Form 4 | |
| Shares held after sale | 423,029 shares | SEC Form 4 | |
| Sold as share of pre-trade holding | 3.6% | Calculated from SEC Form 4 |
Read more: Xometry (XMTR) stock analysis and investment case
Why it matters
The 15,721 shares were about 3.6% of the holding before the trade, so most of the position stayed in place. That matters because Xometry's case rests on scale improving marketplace matching and take rate over time, not on one insider trade. OptimistFi's case is that the marketplace can standardize fragmented custom manufacturing procurement and eventually produce self-funded profit.
The filing is mixed. It shows a director cutting exposure, but the trades were automatic under Rule 10b5-1 plans. Part of the 10/02 sale also covered tax withholding tied to restricted stock units. The 2026-10-01 sales were of shares held indirectly by a spouse, so the trade says less about Altschuler's direct exposure. After the sales, the stake still stands at 423,029 shares.
Browse: stock research on every company OptimistFi covers
What's next
Xometry's next quarterly report is the next scheduled update on the business. If it shows better matching, a steadier take rate or progress toward self-funded profit, that would strengthen OptimistFi's case. Softer results would leave this insider sale as a routine Form 4 event rather than a change in the operating story. That report will matter more than this filing for judging the business thesis.
More from OptimistFi
- XMTR stock: the Xometry thesis, its status and the next test to watch
- Century Therapeutics, Inc. (NASDAQ: IPSC) Adds Two CNTY-813 Batches
- Applied Digital Corporation (NASDAQ: APLD) Brings 250 MW Online
- ON Semiconductor Corporation (NASDAQ: ON) Cuts Its Deal Cost by 19%
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC Form 4 — Xometry, Inc. Form 4 for Randolph Altschuler filed on 2026-10-02
Read the full OptimistFi thesis on Xometry, Inc.: https://optimistfi.com/stocks/XMTR
See what would break the Xometry, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Xometry, Inc. investment case, its status and the next test to watch live on the Xometry, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
